Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Vertex Pharmaceuticals Incorporated — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.96 (market cap $1.92B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 66.4× Invesco DB Commodity Index Tracking Fund's market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DBC | VRTX | |
|---|---|---|
Market Cap | $1.92B | $127.55B |
Volume | 1,375,556 | 1,487,944 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $557.96 |
52-Week Low | $22.07 | $407.37 |
Typical Hold Time | 60 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.96, up 1.38% with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability from 2023's loss. Strong cash flow from operations of $431.54M supports a healthy balance sheet with $1.28B equity and minimal debt.
Outlook remains positive with technical momentum and fundamental recovery, though revenue volatility and asset base contraction from $2.7B in 2021 to $1.3B in 2024 present execution risks. Analyst sentiment is bullish with 16 buy signals, but investors should monitor revenue sustainability amid declining assets.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
